CD276 and neoplasm: It is noteworthy that the risk score is most strongly associated with the emerging immune checkpoint CD276 (B7‐H3), which has recently been reported to be highly overexpressed in a variety of human solid cancers and is often associated with adverse clinical outcome in patients, making it a potential target for tumour immunotherapy.38, 39